

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

CD34-VioBlue, human

RRID:AB_10827793

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-095-393, RRID:AB_10827793

Antibody Information

URL: http://antibodyregistry.org/AB_10827793

Proper Citation: Miltenyi Biotec Cat# 130-095-393, RRID:AB_10827793

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2-2018; Target Distribution bone marrow, cancer stem cells, CNS cells, dendritic cells, endothelial cells, fibroblasts, hematopoietic stem cells, liver, mast cells, osteoblasts; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-182. (RRID:AB_2726008).

Antibody Name: CD34-VioBlue, human

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: AC136

Antibody ID: AB_10827793

Vendor: Miltenyi Biotec

Catalog Number: 130-095-393

Record Creation Time: 20250820T043104+0000

Record Last Update: 20250820T191117+0000

Ratings and Alerts

No rating or validation information has been found for CD34-VioBlue, human.

Warning: Discontinued: 2021

Discontinued: 2-2018; Target Distribution bone marrow, cancer stem cells, CNS cells, dendritic cells, endothelial cells, fibroblasts, hematopoietic stem cells, liver, mast cells, osteoblasts; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-182. (RRID:AB_2726008).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. Cell reports. Medicine, 5(11), 101823.

Omer-Javed A, et al. (2022) Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells. Cell, 185(13), 2248.

Petrillo C, et al. (2018) Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. Cell stem cell, 23(6), 820.